These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 19487930)

  • 1. Principles of antibacterial dosing in continuous renal replacement therapy.
    Choi G; Gomersall CD; Tian Q; Joynt GM; Freebairn R; Lipman J
    Crit Care Med; 2009 Jul; 37(7):2268-82. PubMed ID: 19487930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
    Tegeder I; Neumann F; Bremer F; Brune K; Lötsch J; Geisslinger G
    Clin Pharmacol Ther; 1999 Jan; 65(1):50-7. PubMed ID: 9951430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL
    Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis.
    Heintz BH; Matzke GR; Dager WE
    Pharmacotherapy; 2009 May; 29(5):562-77. PubMed ID: 19397464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetic principles and drug-dosing adjustments during continuous renal replacement therapies (CRRT)].
    Morabito S; Guzzo I; Vitaliano E; Muzi L; Solazzo A; Pistolesi V; Pierucci A
    G Ital Nefrol; 2006; 23 Suppl 36():S127-38. PubMed ID: 17068740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and the most suitable regimen of panipenem/beta mipron in critically ill patients receiving continuous renal replacement therapy: a pilot study.
    Hayakawa M; Ito Y; Fujita I; Iseki K; Gando S
    ASAIO J; 2006; 52(4):398-403. PubMed ID: 16883119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug dosing in continuous renal replacement therapy: general rules.
    Schetz M
    Curr Opin Crit Care; 2007 Dec; 13(6):645-51. PubMed ID: 17975384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug dosing during continuous renal replacement therapy.
    Churchwell MD; Mueller BA
    Semin Dial; 2009; 22(2):185-8. PubMed ID: 19426426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino Acid requirements in critically ill patients with acute kidney injury treated with continuous renal replacement therapy.
    Btaiche IF; Mohammad RA; Alaniz C; Mueller BA
    Pharmacotherapy; 2008 May; 28(5):600-13. PubMed ID: 18447659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.
    DelDot ME; Lipman J; Tett SE
    Br J Clin Pharmacol; 2004 Sep; 58(3):259-68. PubMed ID: 15327585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Continuous renal replacement therapies (CRRT) will remain the most widely adopted dialysis modality in the critically ill].
    Morabito S; Pistolesi V; Cibelli L; Pierucci A
    G Ital Nefrol; 2009; 26(1):13-21. PubMed ID: 19255959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of continuous renal replacement therapy in acute renal failure.
    Klarenbach S; Manns B; Pannu N; Clement FM; Wiebe N; Tonelli M;
    Int J Technol Assess Health Care; 2009 Jul; 25(3):331-8. PubMed ID: 19619352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drugs dosing in intensive care unit during continuous renal replacement therapy].
    Bourquin V; Ponte B; Saudan P; Martin PY
    Nephrol Ther; 2009 Nov; 5(6):533-41. PubMed ID: 19369134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration.
    Joos B; Schmidli M; Keusch G
    Nephrol Dial Transplant; 1996 Aug; 11(8):1582-5. PubMed ID: 8856215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Sánchez-Izquierdo JA; Pedraz JL
    Chemotherapy; 2007; 53(3):194-201. PubMed ID: 17356270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy.
    Trotman RL; Williamson JC; Shoemaker DM; Salzer WL
    Clin Infect Dis; 2005 Oct; 41(8):1159-66. PubMed ID: 16163635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of RIFLE classification on prognosis of critically ill patients with acute kidney injury treated with continuous renal replacement therapy.
    Li WX; Chen HD; Wang XW; Zhao S; Chen XK; Zheng Y; Song Y
    Chin Med J (Engl); 2009 May; 122(9):1020-5. PubMed ID: 19493435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antimycotic drugs under continuous renal replacement therapy].
    Muhl E
    Mycoses; 2005; 48 Suppl 1():56-60. PubMed ID: 15826289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration.
    Bellmann R; Falkensammer G; Seger C; Weiler S; Kountchev J; Joannidis M
    Int J Clin Pharmacol Ther; 2010 Apr; 48(4):243-9. PubMed ID: 20353745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.